According to a study presented at the 56th Annual Meeting of the American Society for Radiation Oncology (ASTRO), stereotactic body radiation therapy (SBRT) offers unique benefits to patients with advanced oligometastatic lung cancer.
Oligometastasis is a category of metastatic cancer, which occurs when cancer cells break away from a primary tumor site and spread to other parts of the body. The cancer is considered an extension of the original tumor, despite spreading to other locations within the body.
The study analyzed the individual data of patients from around the world. Analysis showed that SBRT or surgery can achieve long-term survival in some patients with oligometastatic stage IV non-small cell lung cancer (NSCLC). Results of this study were used to develop a risk-stratification model that could be used as support in identifying which patients are the most appropriate candidates for SBRT or surgery.
At Illinois CyberKnife, we treat primary and metastatic lung cancer with SBRT. During SBRT treatment, the CyberKnife® precisely targets and delivers high-dose radiation directly to the tumor. This nonsurgical treatment method is completed in five or fewer procedures without incisions or sedation. Patients typically return to normal routines immediately following treatment.
For more information on CyberKnife treatment for metastatic cancer, contact Illinois CyberKnife or read our blog series on metastatic cancer.
This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.